登录    
  
首页 > 期刊论文 > 论文摘要
地西他滨单药或联合预激方案治疗骨髓增生异常综合征及急性髓系白血病的临床分析
         
Clinical observation of decitabine alone or in combination with preexcitation regimen in treatment for patients with myelodysplastic syndrome or acute myeloid leukemia

摘    要
目的: 探讨地西他滨单药或联合预激方案治疗骨髓增生异常综合征(myelodysplastic syndrome, MDS)/急性髓系白血病(acute myeloidleukemia, AML)的临床疗效及安全性。
方法: 回顾性分析18例MDS/AML患者接受地西他滨单药或联合预激方案治疗的临床疗效及不良反应。
结果: 18例患者中, 12达完全缓解, 2例达骨髓完全缓解,总有效率为77.8%(14/18)。15例并发感染(83.3%, 15/18); 1例化疗后死亡,化疗相关死亡率为5.6%(1/18)。
结论: 地西他滨单药或联合预激方案治疗MDS/AML的缓解率较高,不良反应可耐受。
标    签 白血病,髓性   骨髓增生异常综合征   地西他滨   Leukemia   myeloid   Myelodysplastic syndrome   Decitabine  
 
Abstract
Objective: To evaluate the therapeutic efficacy and safty of decitabine alone or in combination with pre-excitation regimen in the treatment for patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML).
Methods: The therapeutic efficacy and safty of decitabine alone or in combination with pre-excitation regimen in the treatment for 18 patients with MDS/AML were retrospectively analyzed.
Results: Of the 18 patients, 12 patients achieved complete remission, 2 patients achieved marrow complete remission, and the overall response rate was 77.8% (14/18). The infection emerged in 15 patients (83.3%, 15/18); only one patient died of chemotherapy-related infection (5.6%, 1/18).
Conclusion: The remission rate of patients with MDS/AML receiving decitabine alone or in combination with pre-excitation regimen was high, and the adverse effects can be accepted.

中图分类号 R733.7   DOI 10.3781/j.issn.1000-7431.2015.33.858

 
  购买该论文  中国光学期刊网论文下载说明
      


所属栏目 临床研究

基金项目

收稿日期 2014/12/23

修改稿日期 2015/2/26

网络出版日期

作者单位点击查看


引用该论文: XING Li-na,REN Jin-hai,CAI Sheng-xin,ZHANG Xiao-lei,GUO Xiao-ling,GUO Xiao-nan. Clinical observation of decitabine alone or in combination with preexcitation regimen in treatment for patients with myelodysplastic syndrome or acute myeloid leukemia[J]. Tumor, 2015, 35(5): 544~549
邢丽娜,任金海,蔡圣鑫,张晓蕾,郭晓玲,郭晓楠. 地西他滨单药或联合预激方案治疗骨髓增生异常综合征及急性髓系白血病的临床分析[J]. 肿瘤, 2015, 35(5): 544~549


论文评价
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
分享论文
分享到新浪微博 分享到腾讯微博 分享到人人网 分享到 Google Reader 分享到百度搜藏分享到Twitter

参考文献
【1】中华医学会血液学分会. 骨髓增生异常综合征诊断与治疗中国专家共识(2014年版)[J]. 中华血液学杂志, 2014, 35(11):1042-1048.
 
【2】中华医学会血液学分会. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2011年版)[J]. 中华血液学杂志, 2011, 32(11):804-807.
 
【3】Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J]. Blood, 2006, 108(2):419-425.
 
【4】Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommoendations of the International Working Group (IWG) for diagnosis, standardization of response criteria,treatment outcomes,and reporting standards for therapeutic traials in acute myeloid leukemia[J]. J Clin Oncol, 2003, 21(24):4642-4649.
 
【5】Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment[J]. Cancer, 1981, 47(1), 207-214.
 
【6】Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes:Results of a phaseⅢ randomized study[J]. Cancer, 2006, 106(8):1794-1803.
 
【7】Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomrized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J]. Blood, 2007, 109(1):52-57.
 
【8】Cashen A, Schiller G, Larsen JS, et al. PhaseⅡstudy of low-dose decitabine for the frist-line treatment of older patients with acute myeloid leukemia (AML)[J]. J Clin Oncol, 2010, 28(4):556-561.
 
【9】Yamada K, Furusawas S, Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia:apilot study[J]. Leukemia, 1995, 9(1):10-14.
 
【10】Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines[J]. Clin Cancer Res, 2007, 131(4):4225-4232.
 
【11】高苏, 仇惠英, 金正明. 地西他滨单药及联合半程及全程CAG方案治疗骨髓增生异常综合征和急性髓系白血病疗效观察[J]. 中华血液学杂志, 2014, 35(11):961-965.
 
【12】Wijermans PW, Lubbertm, Verhodf G, et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients[J]. Ann Hematol, 2005, 84(Suppl 13):9-17.
 
【13】Ferrara F. Conventional chemotherapy or hypomethylating agents for older patientts with acute myeloid leukemia[J]. Hematol Oncol, 2014, 32(1):1-9.
 
【14】Ruter B, Wijermans P, Claus R, et al. Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7[J]. Blood, 2007, 110(3):1080-1082.
 
【15】Blum W, Klisovic RB, Hackanson B, et al. PhaseⅠ study of decitabine alone or in combination with valproic acid in acute myeloid leukemia[J]. J Clin Oncol, 2007, 25(25):3884-3891.
 
【16】Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine[J]. Proc Natl Acad Sci U S A, 2010, 107(16):7473-7478.
 
【17】Khan H, Vale C, Bhagat T, et al. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes[J]. Semin Hematol, 2013, 50(1):16-37.
 
【18】Carr BI, Rahbar S, Aseron Y, et al. Carcinogenicity and haemoglobin synthesis induction by cytidine analogues[J]. Br J Cancer, 1988, 57(4):395-402.
 
【19】Saba HI. Decitabine in the treatment of myelodysplastic syndromes[J]. Ther Clin Risk Manag, 2007, 3(5):807-817.
 
【20】Wang J, Yi Z, Wang S, et al. The effect of decitabine on megakaryocyte maturation and platelet release[J]. Thromb Haemost, 2011, 106(2):337-343.
 
相关信息
   标题 相关频次
 地西他滨桥接异基因造血干细胞移植治疗骨髓增生异常综合征和急性髓样白血病的临床可行性和疗效研究
 6
 急性白血病LRP、mdr1、MRP基因表达的预后意义
 6
 CYP1A1*2C多态性与儿童急性淋巴细胞白血病易感性的Meta分析
 2
 105例急性髓系白血病p170、GSTP-1表达分析
 2
 2003-2007年中国肿瘤登记地区白血病发病与死亡分析
 2
 As2O3诱导白血病细胞凋亡过程中Ca2+的变化及其调节
 2
 CTP-OD1-HA和CTP-OD2-HA融合肽对白血病K562细胞裸鼠皮下移植瘤的作用
 2
 DADAG对L1210细胞内Bc1-2及Bc1-XL蛋白表达的影响
 2
 NB4细胞诱导分化过程中WT1、RbAp46及IGFBP-rP1基因表达水平的变化
 2
 RNAi对白血病细胞mdr-1基因和多药耐药表型的影响
 2
 RNA干扰抑制Apollon表达联合川芎嗪可增强白血病细胞对化疗药物的敏感性
 2
 RSK抑制剂BI-D1870对急性白血病细胞增殖的影响
 2
 STAT5诱骗寡核苷酸诱导白血病K562细胞凋亡的研究
 2
 Trx-DMLS-AIF融合蛋白的原核表达及其对白血病K562细胞脱细胞系统的影响
 2
 WT1(17AA+)剪接变异体在白血病中表达
 2
 靶向ABCG2基因的RNA干扰提高K562细胞的化疗敏感性
 2
 靶向HOXA9基因RNAi慢病毒载体增加人急性单核细胞白血病U937细胞的药物敏感性
 2
 靶向HOXA9基因RNAi慢病毒载体增加人急性单核细胞白血病U937细胞的药物敏感性
 2
 靶向激活蛋白激酶PKR诱导白血病K562细胞凋亡
 2
 白血病ID4基因核心启动子区甲基化及其表达
 2
 白血病骨髓基质细胞促进SHI-1细胞体外侵袭及其作用机制探讨
 2
 白血病细胞凋亡与bcl-2和bax-alpha表达的研究
 2
 白血病细胞膜流动性变化的研究
 2
 白血病中肿瘤抑制基因p16的缺失和突变研究
 2
 斑马鱼微肿瘤模型的建立及其在抗血管生成研究中的应用
 2
 不同预激方案诱导白血病细胞株凋亡的机制研究
 2
 沉默HOXA10基因表达联合川芎嗪可逆转K562/ADR细胞的多药耐药性
 2
 地西他滨治疗成人急性髓细胞白血病的临床观察
 2
 多药耐药基因在白血病细胞的高效转移与表达研究
 2
 恶性血液病免疫球蛋白重链和T细胞受体γ基因重排的研究
 2

  热点专题


关于我们  |   联系我们  |   广告投放  |   《肿瘤》杂志社版权所有 《肿瘤》杂志社   © 中国 上海 2014.3
沪ICP备15036656号-2